Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

China’s Direct Genomics introduces the first single molecule genome sequencer for the clinic
  • USA - English


News provided by

HDMZ (On Behalf of Direct Genomics)

Oct 27, 2015, 08:00 ET

Share this article

Share toX

Share this article

Share toX


Shenzhen, China (PRWEB) October 27, 2015 -- Direct Genomics today announced the GenoCare™ Analyzer, the world’s first single molecule genome sequencer that is being engineered exclusively for the clinic. The GenoCare system improves the cost, speed, and quality of clinical genome sequencing by directly reading a patient’s original DNA or RNA molecules.

The GenoCare™ single molecule genome sequencer could push everyday Chinese medicine to be a cutting-edge, worldwide standard,” says Dr. Wang Zhanhui, Professor of Infectious Diseases at Southern Medical University.

Post this

In contrast to the genome sequencing instruments entering clinical use today, Direct Genomics’ GenoCare Analyzer does not require any of the prerequisite steps, such as amplifying (i.e., copying) a patient’s DNA thousands of times, that currently drive up costs and generate potential artifacts in patients’ genetic material.

“We have been working with eminent physicians and scientists in China and around the world to build a novel technology that can make genomics an affordable part of everyday patient care,” says He Jiankui, Ph.D., founder and CEO of Direct Genomics and an Associate Professor at South University of Science and Technology of China.

Direct Genomics’ scientific advisory board includes Stephen Quake, Ph.D., Professor of Bioengineering and Applied Physics at Stanford University; Michael Deem, Ph.D., Professor and Chair of the Department of Bioengineering at Rice University; and J. William Efcavitch, Ph.D., who has led research and development for numerous genomics instruments at Affymetrix, Applied Biosystems, and Helicos BioSciences.

Dr. He announced the GenoCare system today at the Advances in Genome Sequencing Technology conference in Shenzhen, China. Simultaneously, the first data from a prototype GenoCare instrument, was released on bioRxiv.org in a preprint publication, which highlights the sequencing methodology and data quality metrics from the sequencing of clinically relevant mutations in several oncogenes. Accuracy for sequencing EGFR, KRAS, and BRAF genes was found to be 95% on average at 1X coverage and approaching 100% at 5X coverage.

The first three hospitals involved in the GenoCare Early Access Program, which will be open to more organizations in 2016, are Shenzhen Women’s and Children’s Health Hospital, Shenzhen People’s Hospital, and Southern Medical University in Guangzhou, China. Clinicians at these three hospitals are evaluating viral DNA or circulating tumor DNA found in patients’ blood to inform the personalized selection of Hepatitis B antiviral medications or cancer therapeutics.

“Drug resistant Hepatitis B is becoming a huge problem for millions of people infected with the virus in China, which has one-third of the world’s infected population. An affordable system to sequence the viral genome for the basis of drug resistance would allow clinicians to put patients on the right therapeutic choice right away. The GenoCare single molecule genome sequencer could push everyday Chinese medicine to be a cutting-edge, worldwide standard,” says Dr. Wang Zhanhui, Professor of Infectious Diseases at Southern Medical University.

Direct Genomics’ GenoCare analyzer reads a patient’s original DNA molecules by a sequencing-by-synthesis methodology called single molecule targeted sequencing (SMTS). Single molecule sensitivity is achieved through total internal reflectance fluorescence (TIRF) microscopy, in which a precisely angled laser generates a fast-decaying, evanescent wave. This wave concentrates illumination to a patient’s DNA molecules, preventing illumination of unwanted contaminants that would otherwise obscure the faint signal from a single strand of DNA. SMTS also minimizes costs by sequencing solely the regions of a patient’s genome of clinical relevance, such as selected cancer genes known to influence resistance or susceptibility to therapeutics. The GenoCare™ sample preparation protocol requires only a single step, fragmenting the DNA, which further minimizes costs, labor, and the time to result. In the case of FFPE material, sonication may not even be needed.

“The single molecule approach provides a level of confidence appropriate for the clinic. It also presents technical advantages, such as reducing the risk of sample handling errors and allowing the absolute quantitation of gene expression or copy number variations that are important in numerous diseases,” says He.

Earlier this year, Direct Genomics secured worldwide freedom to operate by licensing key single molecule sequencing patents from the California Institute of Technology.

About Direct Genomics
Together with clinicians, Direct Genomics is making genomics an affordable part of everyday patient care. The company’s GenoCare™ instrument is the first singe molecule sequencer built exclusively for the clinic. The technology simplifies genome sequencing by reading the individual and original DNA and RNA molecules directly from a patient’s blood or tissue samples, delivering significant improvements in cost and speed. Established in 2012, Direct Genomics is headquartered in Shenzhen, China and is backed by top institutional and private investors.

Ryan Ferrell, HDMZ (On Behalf of Direct Genomics), http://www.directgenomics.com, +1 3125065202, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.